BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (AMEX: AKN) today announced that the U.S. Food and Drug Administration has granted tentative approval for Akorn’s Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Ophthalmic Solution 0.1% in 2.5 ml and 5 ml dropper bottles. Final approval is expected upon expiry of patent protection for Voltaren® Ophthalmic Solution 0.1% in October 2007.
